Search results
Results From The WOW.Com Content Network
The market for Zantac [15] and its competitors was described in 2005 as 13.5 billion US dollars. [ 16 ] The product's problem was described by The New York Times as being "that a potential cancer-causing contaminant can build up in the drug when stored for long periods."
In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after NDMA was found in samples of the drug.
The French pharmaceutical company Sanofi says it has reached an agreement to resolve 4,000 cases in the U.S., in which plaintiffs are linking the discontinued heartburn drug Zantac — and its ...
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. The drug, approved over four decades ago, was the world's ...
The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
NEW YORK (Reuters) -Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday. Sanofi did ...
In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in samples of the drug.
Delaware's highest court said on Tuesday it will hear an appeal by GSK and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK ...